Analyses Adjusting for Selective Crossover Show Improved Overall Survival with Decitabine Compared with Treatment Choice in DACO-016 Phase III Trial
Abstract
Authors
J. Tomeczkowski A. Güntert P. Thilakarathne J. Diels L. Xiu C. Tapprich